The present application provides methods and compounds of modulating Nrf2 pathway. Methods for treating cancer and neurodegenerative conditions are also provided.

Various aspects of this patent document relate to compositions and methods to purify cannabinoids by crystallization in a water-miscible liquid.

A catalyst molded body, a production method thereof and a method for preparing cyclic ketone using the same, including: (a) producing a mixed powder including a catalyst powder and a binder; (b) producing a slurry by mixing an aqueous alkali hydroxide solution with the mixed powder; and obtaining a catalyst molded body by molding and heat-treating the slurry.

Provided herein are compounds useful in the treatment of bacterial infections, pharmaceuticals comprising the same, and methods of use and preparation thereof.

A drug containing, as an active ingredient, a compound having an antagonistic activity against an EP.sub.2 receptor in the prevention and/or treatment of a disease associated with the activation of an EP.sub.2 receptor, of formula (I-A):

##STR00001##

wherein all symbols have the same meanings as those described in the specification, or a pharmaceutically acceptable salt thereof.

Processes for converting a hydrocarbon reactant into an alcohol compound and/or a carbonyl compound are disclosed in which the hydrocarbon reactant and either a supported chromium (VI) catalyst or a supported chromium (II) catalyst are contacted, optionally with UV-visible light irradiation, followed by exposure to an oxidizing atmosphere and then hydrolysis to form a reaction product containing the alcohol compound and/or the carbonyl compound. The presence of oxygen significant increases the amount of alcohol/carbonyl product formed, as well as the formation of oxygenated dimers and trimers of certain hydrocarbon reactants.

The invention discloses novel intermediates in the synthesis of Calebin A represented by formula 3. The invention also covers processes for the synthesis of Calebin-A and its analogs using compounds of formula 3.

##STR00001##

Oxo-nitrogenated iron complex having general formula (I): in which: R.sub.1 and R.sub.2, identical or different, represent a hydrogen atom; or they are selected from linear or branched, optionally halogenated C.sub.1-C.sub.20, preferably C.sub.1-C.sub.15, alkyl groups, optionally substituted cycloalkyl groups, optionally substituted aryl groups; R.sub.3 represents a hydrogen atom, or it is selected from linear or branched, optionally halogenated C.sub.1-C.sub.20, preferably C.sub.1-C.sub.15 alkyl groups, optionally substituted cycloalkyl groups, optionally substituted aryl groups; X, identical or different, represent a halogen atom such as, for example, chlorine, bromine, iodine, preferably chlorine; or they are selected from. linear or branched C.sub.1-C.sub.20, preferably C.sub.1-C.sub.15, alkyl groups, —OCOR.sub.4 groups or —OR.sub.4 groups in which R.sub.4 is selected from linear or branched C.sub.1-C.sub.20, preferably C.sub.1-C.sub.15, alkyl groups; n is 2 or 3. Said oxo-nitrogenated iron complex having general formula (I) can be advantageously used in a catalytic system for the (co)polymerization of conjugated dienes. ##STR00001##

The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I]

##STR00001##

wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist.

The invention provides substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.